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A Quasi-Experimental Evaluation of Dried Blood Spot Testing through Community 
Pharmacies in the Tayside Region of Scotland. 
Abstract: 
Objective: Comparison of uptake of dried blood spot testing (DBST) for Hepatitis C infection (HCV) 
between community pharmacies and established services.  
Design: Quantitative evaluation of a service development with qualitative process evaluation 
undertaken in parallel. 
Setting:  Six pharmacies from 36 community pharmacies within Dundee City, a large urban 
settlement with high levels of socioeconomic deprivation. 
Participants:  Patients in receipt of Opioid Substition Therapy (OST) not tested for Hepatitis C within 
12 months.   The 6 pharmacies provided OST for approximately 363 patients from a cohort of 1,385 
patients within Dundee City. 
Intervention: Provision of DBST by pharmacists. 
Main Outcome Measure: Receipt of DBST between January and December 2014 
Results: 43 of 143 service users with no record of testing from the 6 community pharmacies 
accepted a DBST.  Of 561 from remaining 1022 service users with no record of testing, 75 were 
tested for HCV (30% Vs 13%). The OR for increased uptake of testing within the 6 pharmacies was 
2.25 (95% CI 1.48 to 3.41, Z statistic = 3.81 p= <0.0001) compared to other services.  The DBST taken 
by the pharmacies provided 12 patients with a reactive test. The process evaluation identified key 
themes important to staff and recipients of the service.  A logic model was constructed. 
Limitations:  Non-experimental service evaluation performed in community pharmacies records 
service activity in one location across single time period. 
Interpretation:  Some evidence that DBST from community pharmacies may be feasible. Service 
users received the service positively. Staff reported that DBST was straightforward and achievable. 
  
Background 
Hepatitis C (HCV) is a blood-borne viral infection causing liver disease.  Around 1% of the population 
may be infected with HCV and around 0.8% are chronically infected 1. The greatest risk of acquiring 
the virus in the UK is through injecting drug use. Patient outcomes from HCV infection vary, with 
25% clearing the infection spontaneously and the remainder becoming chronically infected, risking 
development of cirrhosis and hepatocellular carcinoma. People infected with HCV may show no 
symptoms, presenting with incurable, end-stage disease.  A recent Public Health England report 
highlighted that less than 3% of those known to be infected with HCV are being treated and less than 
half of those infected are known2.  The largest single infected group are those on opiate substitution 
therapy (OST) 3. Research suggests around 40% of people receiving OST have HCV 4, 5. 
The conventional NHS pathway of care is that patients with a history of intravenous drug use or 
those currently prescribed OST should be offered HCV testing 1. Testing is commonly available from a 
range of primary care and third sector providers. Once diagnosed, patients may be referred to nurse 
led treatment pathways, based around hepatology or infectious disease teams in secondary care. 
In current pathways, less than 10% of the OST population are tested for HCV.  Of those tested, at 
very best 25% start treatment in one of the dedicated centres, with 70-80% successfully completing. 
This means that only 2-3% of this vulnerable population receive adequate treatment 2.  The new 
highly effective Directly Acting Antiviral (DAA) drugs achieve cure rates in excess of 90%, with once 
or twice daily tablets for 8-12 weeks and few side-effects 6. 
The use of Dried Blood Spot Testing (DBST) in non-traditional environments has dramatically 
increased detection of HCV 7, 8. DBST has been shown to be a reliable alternative to taking venous 
blood samples and determining HCV status in drug injectors.  With appropriate training it can be 
carried out by all staff.  Several practice-based projects have sought to implement DBST into 
pharmacy practice 9. 
Pharmacists have daily interactions with patients receiving methadone and we hypothesised that 
this relationship could be wielded to deliver increases in rates of testing using a DBST approach.  To 
test this we employed a quasi-experimental design 10 to compare the uptake of DBST for HCV in a 
small group of community pharmacies, with uptake in established services (those in substance 
misuse services, general practices and in third sector organisations). 
 
 
Methods 
A quasi-experimental design was chosen as a pragmatic route to evaluate the feasibility and 
scalability of a service development in community pharmacy, because of uncertainties about the 
effect size and nature of the intervention 11. 
This study was carried out in the city of Dundee, within the Tayside region of Scotland, a large urban 
settlement with significant socio-economic deprivation 12.  There are 36 community pharmacies that 
provide OST for approximately 1,385 patients, within a total population of 148,000 13.  Six 
pharmacies were trained to offer DBST.  Pharmacies were selected if they provided OST supervision 
for at least 30 patients and staff were willing to participate.  Patients in the comparator group were 
prescribed OST and attended a community pharmacy that did not offer DBST.  
Design of the Intervention 
Focus group interviews  
A focus group series was undertaken before implementation to identify service user responses to 
the offer of testing, utilising a co-production approach 14. A purposive sampling strategy recruited 41 
participants in 7 focus groups, to gain a diversity of views (Table 1).  All interviews and focus group 
discussions were recorded as digital audio files and transcribed in full for thematic analysis 15.  
Analysis drew on the constant comparison method, operationalised within a general thematic 
approach 16.  
Table 1: Focus Group Participant details 
  Number of Participants 
Age group at participation Less than 35 years 
35 – 44 years 
45 – 54 years 
Over 55 years 
Did not disclose 
17 
5 
6 
4 
9 
Sex Male 
Female 
31 
10 
Participant category Service User 
Carer 
38 
3 
Focus Group Venue Large Urban Settlement 
Other Urban Settlement 
Accessible Rural Town 
Prison Educational Centre 
Women’s Group 
Peer Mentor’s Group 
10 
10 
6 
7 
4 
4 
Development of Programme Theory 
Figure 1 describes a logic model that was constructed to explicitly identify targets for evaluation and 
data collection.  The process evaluation took cognisance of Normalisation Process Theory 17 using 
the core constructs of coherence, cognitive participation, collective action and reflexive monitoring 
to conceptualise the processes involved with effectiveness of implementation. 
 
Implementation of DBST 
Staff from the six community pharmacies were trained to perform DBST to consenting patients18.  
DBST employs a finger prick of blood, spotted onto protein saving paper.  The sample was tested by 
Medical Microbiology for HCV, HIV and Hepatitis B antibodies 7.  Fourteen staff members from the 
pharmacies attended a 2 hour interactive teaching session.  The six pharmacies were notified which 
of their OST patients had no history of HCV testing, as identified by the central virology laboratory.  
Testing for HCV was offered to each of these individuals.  All individuals with a reactive antibody HCV 
test were offered referral to the specialist hepatitis service. 
Participants’ comments during the training were noted and each pharmacy was visited several times 
to discuss progress.  Notes of these interactions and e-mails from participants were retained for 
analysis.  Testing took place during the last quarter of 2014. 
Post-Testing Interviews 
Semi-structured interviews were conducted with (i) 8 service users and (ii) 10 professionals taking 
part in the study, with all 6 pharmacies represented.  The interviews were conducted using two topic 
guides developed in line with the research aims and programme theory. All interviews were 
recorded as digital audio files and transcribed in full for thematic analysis15, 19.  These data 
contributed to assessment of feasibility and acceptability (including barriers and facilitators); 
identifying any unintended consequences of participation. Transcripts were inductively analysed to 
identify themes emergent from the interviews.  A deductive analysis was also undertaken to 
compare findings with programme theory. 
Quantitative Data collection and analysis 
Data on demographic information, risk factors, laboratory tests, referral, follow-up and treatment 
were collected. The age structures of the intervention and comparator groups were compared by t-
test, as were data on DBST taken by the pharmacies.  An odds ratio was calculated for the numbers 
of service users undertaking testing at pharmacies compared to non-pharmacy services. 
Ethics Approval 
Study documents were submitted to the East of Scotland Research Ethics Service, who confirmed 
that this work did not require Ethical Approval under its terms of the Governance.  Caldicott 
permission was gained to enable access to and analysis of patient information. 
  
Results 
The age structure of the 143 service users (26% of all OST users) with no record of testing from the 6 
pharmacies, together with the 1022 service users of the comparator group are presented in Table 2. 
Table 2: Age structure of service users prescribed OST in Dundee 
Age Intervention 
Cohort 
Intervention 
Cohort (%) 
Comparison 
Cohort 
Comparison 
Cohort (%) 
Total 
Population 
Total 
Population 
(%) 
<19 0 ~ 0 ~ 0 ~ 
20-24 14 4% 23 2% 37 3% 
25-29 51 14% 133 13% 184 13% 
30-34 112 31% 256 25% 368 27% 
35-39 86 24% 239 23% 325 23% 
40-44 61 17% 185 18% 246 18% 
45-49 26 7% 120 12% 146 11% 
50-54 10 3% 48 5% 58 4% 
55-59 3 1% 16 2% 19 1% 
60-64 0 0% 2 0% 2 0% 
65-69 0 0% 1 0% 1 0% 
 363 100% 1023 100% 1386 100% 
Analysis of the age structure of intervention and comparator groups was undertaken. A significant 
difference between the two groups was detected using the two-sided t-test (p<0.05). The 
intervention group were younger by 1.75 years (mean age of 35.6 years) compared to the 
comparison group (mean age of 37.4 years).  The study design meant that intervention and 
comparison groups were not randomised, and therefore equal mean ages of the two groups were 
not expected.  
During the test period, 43 (30%) of the 143 service users from the six community pharmacies 
accepted a DBST.  Within the comparator group 561 from 1022 service users had no history of DBST 
and a total of 75 (13%) patients were tested for HCV by other providers of DBST (30% Vs 13%). The 
OR for increased uptake of testing within the six pharmacies was 2.25 (95% CI 1.48 to 3.41, Z statistic 
= 3.81 p= <0.0001) in comparison to the other services (Table 2).  The six pharmacies identified 12 
patients with a reactive test.  The uptake of DBST by each of the six pharmacies is presented in Table 
3. No significant difference in uptake between the sites could be detected at the p<0.05 level using 
two-sided t-testing. 
 
Table 3: Uptake of testing by pharmacy site 
Pharmacy Site Number of Eligible 
Patients 
Number of tests taken 
(% of eligible patients) 
Number of Positive Tests 
A 23 13 (57) 3 
B 22 11 (50) 4 
C 30 5 (17) 3 
D 26 10 (38) 1 
E 26 3 (12) 1 
F 16 1 (6) 0 
Totals 143 43 (30) 12 
Understanding of context for delivery 
Themes identified from transcript analysis of the focus groups provided information about the 
context for delivery20.  Focus groups discussions demonstrated an understanding of HCV including 
latency and effects on general health (Figure 2).  Participants could talk about cirrhosis and cancer.  
Participants knew about the burden of treatment of interferon-based regimes.  Several clients knew 
about the cost of the new treatments. 
Hepatitis C was viewed as a “dirty disease” caught from sharing needles.  It was unacceptable to 
admit to having HCV and participants feared social exclusion if found out.  Participants described the 
shame they expected to feel if their family discovered they had HCV and spoke about “letting them 
down”.  The fear of being found out contributed to reticence about testing. 
What factors influenced client recruitment and participation? 
The transcripts from the post-test interviews demonstrated that service users had both positive and 
negative perceptions of testing.  Interviewees clearly thought that pharmacies were a good place to 
be tested and valued this service and the positive relationships built with pharmacy staff.  Lack of 
money meant travelling to a local hospital was a barrier to clinic attendance.  Service users talked 
vividly about their diminished horizons: they felt this was due to their dependence on drugs and lack 
of money. Pharmacies however were viewed as part of the local community. 
Some service users’ previous experiences of stigma and discrimination when attending a pharmacy 
led to caution and suspicion when they were offered testing.  One client complained that they were 
offered DBST stood at the dispensary counter, rather than in the private consultation room.  Clients 
with negative experiences suggested staff would need intensive training before offering the service.  
Some clients expressed the wish for a better explanation about how the test worked and what the 
results might mean.  Clients with positive experiences raised no issues for service improvement. 
Several interviewees distinguished themselves from other “junkies”.  These interviewees would 
describe their plans for recovery and would describe their relationship with a partner or young 
family.  These individuals believed that service users with more chaotic lives were less likely to be 
tested. 
What feedback on staff training and implementation was received? 
Staff interviewees had clear views about successful implementation.  Staff considered that strong 
leadership and involving all the team were necessary.  Comments such as “a great opportunity”, “an 
obvious thing to do” and “a no brainer” were made.  The degree of enthusiasm for new roles and 
positive relationships with patients were important.  Only one individual viewed the development 
“as a step beyond what pharmacies do”.  There were some initial anxieties expressed about 
potential contact with infected blood.  Some staff viewed DBST as a pharmacist’s role, whereas 
others thought it was a team role. 
The training was evaluated positively, with comments received about the simplicity of DBST.  Several 
teams took lancets and protein-saving cards with them to practice the technique.  Implementation 
was viewed as most successful where all the team were involved. 
Some staff expressed concern about offering DBST when prescription dispensing workload was high. 
An identified solution was to use time slots when workload was less.  Time barriers were most 
important where DBST was seen as a pharmacist role 
Figure 2: Examples of focus group quotations 
What do service users understand by hepatitis C infection and how they obtain testing and 
treatment? 
Perceptions of disease  
“my daughter and partner have it. It can lie dormant. it makes you feel very tired and you have no 
appetite” (Participant 5, Carer, December 11) 
 “You could have hepatitis even though, you could be stable on methadone for years then find out 
you’ve got hepatitis” (Participant 35, 22 April) 
Perceptions of testing and treatment 
I think more people have got it done since they started doing that ‘cause it’s easier (DBST) 
(Participant 37, 22 April) 
 “What they do is they have a look at your white blood cells count and things like that and how your 
system is reacting to it and whether or not.  See, when you get the finger prick test for Hepatitis it’ll, 
if you have been exposed to the Hepatitis virus at all, it will come back positive.  That doesn’t 
necessarily mean to say that you have got Hepatitis, so what they then is they will do a blood test 
and start talking about counts and things like that as its really confusing” (Participant 19, 25 
February) 
You see my partner is really skinny as it is and I think he will loose, everybody;s different are they, I 
think he will loose a lot of weight and I think it affects them mentally as well (Participant 33, 7 
March) 
Preferences for obtaining treatment 
It would have tae be someplace where dinnae have tae travel everywhere where its gonnae cost 
them money that they have nae always got that’s, that’s what I feel is a big thing having tae travel 
tae Ninewells all the time (Participant 27, 5 March) 
I think that’s one of the things that’s gonnae be down tae the individual, it depends on how chaotic 
their lifestyle is otherwise there’s gonnae be a lot of money wasted there.  And I take it this new stuff 
isnae cheap coz it never is when its first introduced. (Participant 22, 5 March) 
“Well I say your pharmacy because like I say you’re there every day, you’re only, some people dinna 
even go to the DPC once a month.  So and then you forget your appointment, some people forget 
their appointment at the DPC but you’re guaranteed to go for your methadone every day so” 
(Participant 36, 22 April) 
Aye but you could be going tae the pharmacy for anything you see, so this again de-stigmatising.  
Nobody knows what they’re in there for, it could be a drug problem it could be… anything 
(Participant 19, 25 February) 
 
Discussion 
Key findings 
This study provides some evidence that pharmacies may be a feasible site from which to offer DBST.  
People receiving OST were more likely to accept a DBST from a pharmacy than from other local 
providers.  The evaluation of the implementation provides some evidence of the context for delivery 
and the mechanisms that may lie behind the outcomes observed20.  Contextual factors included: 
expectations and experiences of stigma and discrimination; fears about confidentiality; the limited 
horizons of people receiving OST and the poverty they experience.  Identified mechanisms that may 
influence uptake included the presence of established relationships with pharmacy staff; a pre-
existing reason for attending the pharmacy for OST and  the proximity of the pharmacy within the 
local community. 
Review of programme theory 
The programme theory provided a useful structure from which to consider the process evaluation 
and enabled a series of insights into the barriers and facilitators to effective implementation.  In 
particular, we valued insights into the context that testing in pharmacies created for service users 
and the meaning that such testing may have.  The evaluation also provided an indication about how 
the attitudes and behaviours of staff towards the intervention contributed to success or otherwise. 
A number of barriers to uptake of testing and treatment including fear of blood tests21, adverse 
socioeconomic and family circumstances, as well as fear of treatment side-effects were identified in 
other studies as well as being identified in this study22.  Evidence suggests that offering DBST may 
increase the uptake of HCV testing, when compared to venepuncture, although this finding may also 
reflect increased availability and access when a DBST technique is used 7, 23, 24. Community-based 
settings for HCV services may also increase acceptance and uptake of testing 25, 26, 27, 28.  Provision of 
on-site testing may also have positive effects on uptake, due to the proximity of the testing offer23. 
Different settings have been used to increase the uptake of testing and treatment including testing 
from methadone maintenance services29, 30, in city homeless shelters23 and mental health sites26.  
Little work has utilised the daily interaction with community pharmacists to increase testing, follow-
up and treatment adherence.  A pilot project introducing DBST in a community pharmacy was 
undertaken in England in 200931, 32.  The pilot concluded that community pharmacies provide a 
useful route to diagnosing HCV patients and could successfully reach at-risk groups. The pilot service 
was most successful when pharmacists worked closely with local drug services and where 
pharmacists were proactive in discussing risks with clients.  Several limitations were noted, including 
the availability of consultation rooms in pharmacies, the provision of adequate staffing to manage 
the normal workload of a pharmacy and also the motivation and commitment of the pharmacist to 
support this new activity.  Similar factors were identified in this current study.  The provision of 
clinical standard consultation rooms is now very common in Scotland. 
The stigma associated with both OST prescription and HCV infection was strongly recognised in this 
study.  A systematic review of qualitative research into Hepatitis testing, recommended framing the 
positive outcomes of testing in terms of responsibility for individual health and the health of family 
and community, building positive relationships and targeting stigmatising attitudes23. 
Limitations 
The primary limitation of the current feasibility study is the small group of pilot pharmacies.  Further 
work is now required to establish stronger evidence that pharmacies can positively influence uptake 
in a greater variety of locations. 
The intervention group had a slightly lower average age than the comparitor group.  Since patients 
on OST undertake a pathway to recovery, a younger patient group may be expected to have a less 
stable situation than an older group and be less motivated to engage in healthcare interventions. 
Some variance in service delivery is common place in pharmacies and in health services generally. 
The variance may be explained by a range of factors including staffing levels, building configuration, 
profile of the client group, as well as staff attitudes.  With more experience of delivering training for 
and services, as well as role acceptance, it is expected that some of the variance will diminish. 
Interpretation 
The study design provided a rapid and simple method of demonstrating that the systems required 
for DBST testing can be established successfully in community pharmacies.  The daily attendance at 
the pharmacy provides an unexploited opportunity to deliver health interventions.  OST recipients 
usually lived a short walk from their pharmacy 
An increase proportion of OST service users accessed DBST from a pharmacy, compared to other 
providers.  Knowledge of potential issues with implementation should assist with creation of 
effective service delivery.  Further work to evaluate the outcomes associated with this service 
configuration is required34. The identified barriers to the uptake of testing in this study were 
overcome by local availability of the pharmacies and positive relationships with pharmacy staff. 
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